Get the Stockscreener App
0.4274
15.38%
-0.0777
After Hours:
.42
-0.0074
-1.73%
Karyopharm Therapeutics Inc stock is traded at $0.4274, with a volume of 1.75M.
It is down -15.38% in the last 24 hours and down -73.45% over the past month.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
See More
Previous Close:
$0.5051
Open:
$0.49
24h Volume:
1.75M
Relative Volume:
1.15
Market Cap:
$9.69M
Revenue:
$151.12M
Net Income/Loss:
$-194.97M
P/E Ratio:
-0.0283
EPS:
-15.0871
Net Cash Flow:
$-59.11M
1W Performance:
-34.24%
1M Performance:
-73.45%
6M Performance:
-94.84%
1Y Performance:
-92.40%
1-Day Range:
$0.3958
$0.5016
1-Week Range:
$0.3958
$0.6896
52-Week Range:
$0.3958
$10.99
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
Name
Karyopharm Therapeutics Inc
Sector
Industry
Phone
617-658-0600
Address
85 WELLS AVENUE, NEWTON, MA
Compare KPTI vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
0.4274 | 9.69M | 151.12M | -194.97M | -59.11M | -15.09 |
VRTX
Vertex Pharmaceuticals Inc
|
485.22 | 122.98B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
216.25 | 86.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
753.12 | 77.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.64 | 50.47B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.44 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-31-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-31-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-10-26 | Initiated | Rodman & Renshaw | Buy |
| Feb-05-26 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-13-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-16-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-11-25 | Resumed | H.C. Wainwright | Buy |
| Jan-19-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-09-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-06-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-06-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-02-20 | Initiated | Morgan Stanley | Overweight |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-17-20 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-23-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-05-19 | Reiterated | H.C. Wainwright | Buy |
| Jul-05-19 | Reiterated | Robert W. Baird | Outperform |
| Mar-01-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-28-19 | Reiterated | BofA/Merrill | Underperform |
| Feb-27-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jan-03-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Dec-03-18 | Initiated | B. Riley FBR | Buy |
| Nov-09-18 | Upgrade | Wedbush | Neutral → Outperform |
| May-24-18 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-02-18 | Resumed | Leerink Partners | Outperform |
| Nov-15-17 | Resumed | H.C. Wainwright | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-08-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-30-16 | Upgrade | Jefferies | Hold → Buy |
| Aug-18-16 | Initiated | H.C. Wainwright | Buy |
| Jun-28-16 | Initiated | Robert W. Baird | Outperform |
View All
Karyopharm Therapeutics Inc Stock (KPTI) Latest News
Two Acorn funds account for one manager’s reported stake in Karyopharm (KPTI). - Stock Titan
Karyopharm Therapeutics stock falls 13.72 percent as liquidity tightens - AD HOC NEWS
A tax-related sale: Karyopharm (KPTI) accounting chief sells 378 shares at $1.19 each. - Stock Titan
A new Karyopharm hire gets 333 stock units, vesting over 3 years if they stay. - Stock Titan
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Karyopharm Therapeutics (KPTI) Stock News - Stock Titan
More than 5% of Karyopharm Therapeutics (KPTI) is reported under one manager's name, tied to two funds. - Stock Titan
Two partnerships report Karyopharm (KPTI) shares; their manager has shared voting power. - Stock Titan
KPTI Slides As Legal, Cash Pressures Rattle Traders - StocksToTrade
Form 8K Karyopharm Therapeutics Inc For: 11 September By Investing.com - Investing.com South Africa
Karyopharm Skips $15.8 Million Debt Payment, Warns of Going-Concern Risk - Minichart
KPTI Looks 64.4% Undervalued on GF Value™ but Faces Significant Financial Struggles - GuruFocus
Form 8K Karyopharm Therapeutics Inc For: 11 September By Investing.com - Investing.com Canada
Karyopharm TherapeuticsEnters Forbearance Agreement And Waiver On Sept 10, 2026SEC Filing - TradingView
Karyopharm Wins Forbearance to Oct. 15, Will Issue $20M 0% Convertible Preferred - TradingView
Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use - Yahoo Finance
Karyopharm Therapeutics Stock Price Forecast. Should You Buy KPTI? - StockInvest.us
Israel Englander group discloses new Karyopharm stake (NASDAQ: KPTI) - Stock Titan
Karyopharm Therapeutics (KPTI) Stock Fair Value Falls After Split Analyst Views On Trial Updates - Yahoo Finance
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Karyopharm
Karyopharm Seeks FDA Approval for XPOVIO Plus Ruxolitinib in Myelofibrosis - Cure Today
A Second Drug for a Disease That Has Only Ever Had One: Karyopharm Files for Selinexor Plus Ruxolitinib in Myelofibrosis - Onco'Zine
Karyopharm Therapeutics Submits Supplemental New Drug Application to the Fda for Xpovio Plus Ruxolitinib for Patients with Myelofibrosis - marketscreener.com
Karyopharm Therapeutics submits sNDA seeking accelerated approval for selinexor plus ruxolitinib in myelofibrosis - TradingView
KPTI Looks 60.5% Undervalued on GF Value™ Amid Challenging Funda - GuruFocus
Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis - Karyopharm
Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis - TradingView
Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc.KPTI - FinancialContent
Karyopharm’s (KPTI) Big Cancer Bet Faces A Ticking Clock - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc.KPTI - YCharts
Karyopharm (KPTI) Q2 2026 Earnings Call Transcript - AOL.com
KPTI Stock Price and Chart — NASDAQ:KPTI - TradingView
Earnings Release: Here's Why Analysts Cut Their Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Price Target To US$6.40 - simplywall.st
Earnings Release: Here's Why Analysts Cut Their Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Price Target To US$6.40 - simplywall.st
RA Capital boosts Karyopharm (KPTI) stake to 9.99% beneficial ownership cap - Stock Titan
Karyopharm Therapeutics (KPTI): Commodore Capital now reports 0.0% ownership - Stock Titan
Karyopharm Therapeutics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Conferencia de resultados del 2T de 2026 de Karyopharm (KPTI): foco en la sNDA de selinexor y la liquidez - TradingKey
Karyopharm (KPTI) Ergebniskonferenz Q2 2026: Fokus auf Selinexor-sNDA und Liquidität - TradingKey
Karyopharm Therapeutics Inc (KPTI) Earnings, Actual EPS, EPS Estimates & Results - Stocktwits
Karyopharm Therapeutics Inc (KPTI) (Q2 2026) Earnings Call Highlights: SENTRY Trial Success and ... - Yahoo! Finance Canada
Karyopharm Therapeutics Inc (KPTI) (Q2 2026) Earnings Call Highl - GuruFocus
It's crunch time for Karyopharm as company faces potential default next month - Fierce Pharma
Karyopharm Therapeutics has cash to last only into next month - The Business Journals
Karyopharm Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Karyopharm Q2 2026 slides: myelofibrosis sNDA planned for August By Investing.com - Investing.com Australia
Karyopharm Q2 2026 slides: myelofibrosis sNDA planned for August By Investing.com - Investing.com India
Karyopharm Therapeutics Q2 2026 Earnings Call Transcript - marketbeat.com
Karyopharm Therapeutics Inc Stock (KPTI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Karyopharm Therapeutics Inc Stock (KPTI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Abate Kristin | Chief Accounting Officer |
Sep 01 '26 |
Sale |
2.02 |
19 |
38 |
23,782 |
| Poulton Stuart | EVP, Chief Development Officer |
Jul 28 '26 |
Sale |
7.10 |
189 |
1,342 |
94,632 |
| Poulton Stuart | EVP, Chief Development Officer |
May 14 '26 |
Sale |
9.50 |
403 |
3,828 |
94,821 |
| Rangwala Reshma | EVP & Chief Medical Officer |
May 14 '26 |
Sale |
9.50 |
408 |
3,876 |
56,829 |
| Cheng Sohanya Roshan | EVP & Chief Commercial Officer |
May 14 '26 |
Sale |
9.50 |
324 |
3,078 |
107,940 |
| Abate Kristin | Chief Accounting Officer |
May 14 '26 |
Sale |
9.50 |
53 |
504 |
23,801 |
| Paulson Richard A. | President and CEO |
May 14 '26 |
Sale |
9.50 |
2,203 |
20,928 |
269,747 |
| Mano Michael | EVP, CLO&Secretary |
May 14 '26 |
Sale |
9.50 |
266 |
2,527 |
94,398 |
| Rangwala Reshma | EVP & Chief Medical Officer |
Apr 21 '26 |
Sale |
8.94 |
449 |
4,014 |
56,290 |
| Rangwala Reshma | EVP & Chief Medical Officer |
Mar 02 '26 |
Sale |
9.41 |
5,066 |
47,669 |
56,739 |
4.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):